Lantern Pharma Announces Upcoming Conference Presentations

Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its CEO, Panna Sharma, will participate in three virtual investor events this December. Notable events include the Diamond Equity Research Emerging Growth Invitational on December 1, 2020, and the Benzinga Global Small Cap Conference on December 9, 2020. Lantern Pharma utilizes its proprietary RADR® A.I. platform for oncology drug development, focusing on drug repurposing and improving patient outcomes by identifying suitable candidates based on genomic profiles.

DALLAS, Nov. 24, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence ("A.I.") platform to transform the pace, risk and cost of oncology drug discovery and development, and identify patients who will benefit from its targeted oncology drug candidates, announced that Panna Sharma, CEO and President, will participate in the following investor events in December:

1. Diamond Equity Research Emerging Growth Invitational
   Date/time: December 1, 2020 at 12:20 pm ET
   Zoom Link for Live Event: https://us02web.zoom.us/webinar/register/WN_2S0ftHykTdSY_7HJCjGZAQ
   
   
2. hubXchange Virtual US East Coast AI in Drug Discovery Xchange
   Date/time: December 2, 2020 at 12:20 pm ET
   Location: https://www.hub-xchange.com/ai-in-drug-discovery-2020
   
   
3. 2020 Benzinga Global Small Cap Conference
   Date/time: December 9, 2020 at 3:30 p.m. ET
   Zoom Link for Live Event: https://us02web.zoom.us/j/89571252065

All meetings and presentations will be held virtually. Investors and media interested in meeting with Panna Sharma should contact Marek Ciszewski, J.D., at: Marek@LanternPharma.com or +1.628.777.3167. Registered conference attendees may also request meetings through the respective conference registration system.

About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.lanternpharma.com or follow the company on Twitter @lanternpharma

Contact:
Marek Ciszewski, JD
Director, Investor Relations
628-777-3167
marek@lanternpharma.com

Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this press release include, among other things, statements relating to: the potential advantages of our RADR^® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of any of our drug candidates; our strategic plans to expand the number of data points that our RADR^® platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR^® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc. or our management "believes," "expects," "anticipates," "estimates," "plans" (and similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as the impact of the COVID-19 pandemic, the results of our clinical trials, and the impact of competition. Additional factors can be found in the Risk Factors section in our final prospectus, dated June 10, 2020, for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-upcoming-conference-presentations-301179612.html

SOURCE Lantern Pharma

FAQ

What investor events will Lantern Pharma (LTRN) CEO participate in December 2020?

Lantern Pharma CEO Panna Sharma will participate in three events: Diamond Equity Research Emerging Growth Invitational on December 1, hubXchange AI in Drug Discovery Xchange on December 2, and the Benzinga Global Small Cap Conference on December 9, 2020.

When is the Diamond Equity Research Emerging Growth Invitational for Lantern Pharma (LTRN)?

The Diamond Equity Research Emerging Growth Invitational for Lantern Pharma is scheduled for December 1, 2020, at 12:20 pm ET.

What is Lantern Pharma's (LTRN) focus in drug development?

Lantern Pharma focuses on oncology drug development using its RADR® A.I. platform, aiming to improve patient outcomes by repurposing drugs and identifying patients most likely to benefit.

How is Lantern Pharma (LTRN) using artificial intelligence in drug discovery?

Lantern Pharma leverages its RADR® A.I. platform to streamline drug discovery, reducing risk and cost while identifying patient populations that are likely to respond to specific drug candidates.

What are the dates for the 2020 Benzinga Global Small Cap Conference featuring Lantern Pharma (LTRN)?

The 2020 Benzinga Global Small Cap Conference featuring Lantern Pharma is set for December 9, 2020, at 3:30 p.m. ET.